A review of the proteasome inhibitor bortezomib in multiple myeloma

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.5, Iss.6, 2004-06, pp. : 1321-1331

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib: A Review of its Use in Patients with Multiple Myeloma

By Curran Monique P. McKeage Kate

Drugs, Vol. 69, Iss. 7, 2009-05 ,pp. : 859-888

Adis International

Access to resources Recommend Favorite

Bortezomib in multiple myeloma

By Terpos Evangelos Roussou Maria Dimopoulos Meletios-Athanassios

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 5, 2008-05 ,pp. : 639-654

Informa Healthcare

Access to resources Recommend Favorite

Bortezomib for multiple myeloma

By Popat Rakesh Joel Simon Oakervee Heather Cavenagh Jamie

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 10, 2006-07 ,pp. : 1337-1346

Informa Healthcare

Access to resources Recommend Favorite

An expanding VISTA for bortezomib in multiple myeloma

Inpharma, Vol. 1, Iss. 1645, 2008-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma

By Opoku-Ansah John Ibarra-Rivera Tannya R. Pirrung Michael C. Bachmann André S.

Pharmaceutical Biology (Formerly International Journal of Pharmacognosy), Vol. 50, Iss. 1, 2012-01 ,pp. : 25-29

Informa Healthcare

Access to resources Recommend Favorite